Cancer Letters · 2018 · 204 citations · 50 references
Life SciencesImmunologyPharmacologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCell-mediated ImmunityEffector T Cell FunctionImmune Checkpoint InhibitorsImmune CheckpointsImmune Effector MoleculesPd-1 SignalingPd-l1 BlockadeProgrammed Cell Death Ligand 1 RegulationProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 UpregulationTrastuzumab Resistance
50
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations
Medicine, Immunology, Oncology +16